ClinicalTrials.gg
CompletedNCT01298492OPERA IIUpdated Jun 3, 2021Results posted

A Study To Monitor Long-Term Treatment With PF-00547659

A Phase 2 interventional study of PF-00547659 in Crohn's Disease, sponsored by Shire. Completed at 112 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-03.

Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
268
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies in Crohn Disease by Takeda — 12 open to participants now, 14 under way, 7 of them phase 3. Crohn Disease · Takeda.

Enrollment
12th of 51
268 · median 100
Started
2011
with 1 other
Phase 2
13 of 86
3 open now
Registered
10th of 86
by date

Among the 86 studies in Crohn Disease by Takeda, this one is the 12th largest by enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2011, is one of 13 in phase 2, and was the 10th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

12 of the 86 studies in Crohn Disease by Takeda are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Crohn Disease by Takeda, or all of them as a file.
02

Study summary

This study provides open-label drug to eligible patients who have completed a prior study of PF-00547659. The primary endpoint for this study is long-term safety.

Read the detailed description

The rationale for conducting this open-label extension (OLE) study is primarily to evaluate long term safety of PF 00547659. This protocol also provides the opportunity for continued treatment for subjects responding to treatment from the feeder study. It also provides an opportunity for initial treatment for subjects randomized to placebo in the feeder study. This is a multi center Phase 2, open label, safety extension study for feeder studies which evaluate PF 00546759 in subjects with moderate to severe Crohn's disease. Subjects eligible for this study will have completed the 12 week double blind induction period in study A7281006 and will be stratified by responders or non responders based on change in CDAI in that study, without unblinding treatment assignment from study A7281006. Additionally, subjects who have completed study A7281008 with a clinical response, as defined by that protocol, will also be eligible for this study and treated as "responders". All subjects entering this study must have discontinued immunosuppressant therapy.

Subjects entering this study will be given a 75 mg SC dose at baseline and then every 4 weeks through Week 72. After the active treatment period, the subjects will enter a 24 month follow up period including 6 monthly visits followed by 18 month extended contact (every 6 month telephone contacts). At Week 96, subjects will undergo an End of Study visit but will continue the every 6 month telephone contacts until Week 168.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Active Crohn's disease
  • Anti-TNF Refractory
  • Immunosuppressant Refractory
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects between 18 and 76 years of age.
  • Subjects previously enrolled in study A7281006 who have completed the blinded 84 day (12 week) induction period or in study A7281008 who have completed Week 12 and have demonstrated a clinical response as defined by that protocol.

Exclusion criteria

Exclusion Criteria:

  • Subjects that have completed Day 84 (Week 12) of a PF-00547659 study but have experienced serious event(s) related to the product, an unstable medical condition, or any other reason, in the opinion of the investigator, would hinder entry or participation in this study.
  • Subjects who are taking any dose of azathioprine, 6-mercaptopurine or methotrexate.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Enrollment
268 participants (actual)

Study arms

  • Experimental
    Open-Label Treatment

    Subjects eligible for this study will have completed the 12 week double blind induction period in study A7281006 and will be stratified by responders or non responders based on change in CDAI in that study, without unblinding treatment assignment from study A7281006. Additionally, subjects who have completed study A7281008

    Drug: PF-00547659

Interventions

  • 75 mg SC once monthly for 72 weeks. Subjects may escalate to 225 mg or de-escalate to 22.5 mg one time.

06

What researchers measure

Primary outcomes

  1. Number of Participants With On-Treatment Adverse Events (AEs), AEs Led to Withdrawal, and Serious Adverse Events (SAEs)

    AEs included adverse drug reactions, illnesses with onset during the study, exacerbation of previous illnesses, clinically significant changes in physical examination findings and abnormal objective test findings (ECG, laboratory). An SAE was defined as any AE at any dose that resulted in death; was life threatening (immediate risk of death); required in-subject hospitalization or prolongation of existing hospitalization; resulted in a persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); or resulted in congenital anomaly/birth defect.

    Time frame: From start of study treatment up to Week 72 (Treatment Period)

Secondary outcomes

  1. Number of Participants With Positive Anti-Drug (PF-00547659) Antibodies

    Positive Anti-Drug Antibodies result was defined as ADA titre value greater than or equal to (\>=) 4.64 at at least one of the time points.

    Time frame: Baseline up to Week 96

  2. Serum Trough Concentrations of PF-00547659 Versus Time

    Serum trough concentrations of PF-00547659 were analyzed using population Pharmacokinetic (PK) methodology.

    Time frame: Week 4,8,12,16,20,24,28,32,36,40,44,48,52,56,60,64,68,72,76,80,84,88,92,96

07

Results

Posted Aug 31, 2017

Participant flow

The study was conducted at 81 centers in Austria, Belgium, Canada, France, Germany, Japan, Netherlands, Norway, Poland, Republic of Korea, Serbia, Slovakia, South Africa, Spain and United States between 22 July 2011 (first participant first visit) and 27 July 2016 (last participant last visit).

Participant flow — Overall Study
MilestonePF-00547659 75 mg
Started268
Completed149
Not completed119
Withdrew: Death2
Withdrew: Insufficient clinical response22
Withdrew: Lost to follow-up12
Withdrew: Withdrawal by subject47
Withdrew: Other (unspecified)7
Withdrew: Withdrawn due to pregnancy1
Withdrew: Protocol violation2
Withdrew: Adverse event(related to study drug)8
Withdrew: Adverse event(not related to study drug)18

Outcome measures

PrimaryNumber of Participants With On-Treatment Adverse Events (AEs), AEs Led to Withdrawal, and Serious Adverse Events (SAEs)

AEs included adverse drug reactions, illnesses with onset during the study, exacerbation of previous illnesses, clinically significant changes in physical examination findings and abnormal objective test findings (ECG, laboratory). An SAE was defined as any AE at any dose that resulted in death; was life threatening (immediate risk of death); required in-subject hospitalization or prolongation of existing hospitalization; resulted in a persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); or resulted in congenital anomaly/birth defect.

Time frame:
From start of study treatment up to Week 72 (Treatment Period)
Reported as:
Count of participants · Participants
Number of Participants With On-Treatment Adverse Events (AEs), AEs Led to Withdrawal, and Serious Adverse Events (SAEs)
ParticipantsPF-00547659 75 mg
Participants With AEs249
Participants With AEs Led to Withdrawal53
Participants With SAEs80
SecondaryNumber of Participants With Positive Anti-Drug (PF-00547659) Antibodies

Positive Anti-Drug Antibodies result was defined as ADA titre value greater than or equal to (\>=) 4.64 at at least one of the time points.

Time frame:
Baseline up to Week 96
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-Drug (PF-00547659) Antibodies
ParticipantsPF-00547659 75 mg
Number of Participants With Positive Anti-Drug (PF-00547659) Antibodies63
SecondarySerum Trough Concentrations of PF-00547659 Versus Time

Serum trough concentrations of PF-00547659 were analyzed using population Pharmacokinetic (PK) methodology.

Time frame:
Week 4,8,12,16,20,24,28,32,36,40,44,48,52,56,60,64,68,72,76,80,84,88,92,96
Reported as:
Mean · nanogram per milliliter (ng/mL)
Serum Trough Concentrations of PF-00547659 Versus Time
nanogram per milliliter (ng/mL)PF-00547659 75 mg
Week 46673 ± 6634.2
Week 86064 ± 4455.3
Week 128040 ± 6293.1
Week 169563 ± 7285.4
Week 2010400 ± 8438.6
Week 2410450 ± 7934.6
Week 2810780 ± 9211.0
Week 3211920 ± 10675
Week 3612460 ± 9717.1
Week 4012570 ± 10077
Week 4412960 ± 10999
Week 4813170 ± 11108
Week 5213560 ± 11388
Week 5613930 ± 11191
Week 6014130 ± 11095
Week 6414360 ± 11290
Week 6814990 ± 12883
Week 7213910 ± 10554
Week 7610520 ± 10082
Week 803555 ± 5339.8
Week 841129 ± 2634.7
Week 88403.8 ± 1522.6
Week 92154.2 ± 1001.9
Week 9654.73 ± 487.07

Adverse events

Collected over From Start of Study Treatment up to Safety Follow up (Week 96). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-00547659 75 mg2/268 (0.7%)118/268 (44%)206/268 (76.9%)
Most frequent serious events
Showing 10 of 87
Most frequent serious events
EventPF-00547659 75 mg
Crohn's diseaseGastrointestinal disorders44/268
Anal abscessInfections and infestations10/268
Anal fistulaGastrointestinal disorders7/268
IleusGastrointestinal disorders4/268
Small intestinal obstructionGastrointestinal disorders4/268
PneumoniaInfections and infestations4/268
Abdominal painGastrointestinal disorders3/268
NauseaGastrointestinal disorders3/268
VomitingGastrointestinal disorders3/268
Clostridium difficile infectionInfections and infestations3/268
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPF-00547659 75 mg
ArthralgiaMusculoskeletal and connective tissue disorders83/268
Crohn's diseaseGastrointestinal disorders79/268
NasopharyngitisInfections and infestations54/268
Abdominal painGastrointestinal disorders49/268
HeadacheNervous system disorders35/268
NauseaGastrointestinal disorders32/268
Back painMusculoskeletal and connective tissue disorders28/268
PyrexiaGeneral disorders27/268
DiarrhoeaGastrointestinal disorders24/268
VomitingGastrointestinal disorders23/268

Baseline characteristics

The modified intent-to-treat (mITT) population included all enrolled participants who received at least 1 dose of investigational product.

Age, Continuous
Age, Continuous(year)PF-00547659 75 mg
Mean36.5 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)PF-00547659 75 mg
Female151
Male117
08

Study locations

112 sites
  • UCSD Medical Center - Thorton Hospital
    La Jolla, California 92037, United States
  • Community Clinical Trials
    Orange, California 92868, United States
  • GastroDiagnostics
    Orange, California 92868, United States
  • Clinical Research of the Rockies
    Lafayette, Colorado 80026, United States
  • Rmga - Rmcr
    Thornton, Colorado 80229, United States
  • Rocky Mountain Gastroenterology Associates
    Thornton, Colorado 80229, United States
  • MGG Group Co., Inc.
    Washington, District of Columbia 20006, United States
  • Florida Center for Gastroenterology
    Largo, Florida 33777, United States
  • Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • University of Miami Crohn's and Colitis Center
    Miami, Florida 33136, United States
  • University of Miami Hospital and Clinic (IP Shipment Only)
    Miami, Florida 33136, United States
  • University of Miami Hospital and Clinic
    Miami, Florida 33136, United States
  • University of Miami Hospital
    Miami, Florida 33136, United States
  • Citrus Ambulatory Surgery Center
    Orlando, Florida 32806, United States
  • Internal Medicine Specialists
    Orlando, Florida 32806, United States
  • Heartland Medical Research, Inc.
    Clive, Iowa 50325, United States
  • Iowa Digestive Disease Center
    Clive, Iowa 50325, United States
  • Iowa Endoscopy Center (Colonoscopy Only)
    Clive, Iowa 50325, United States
  • Metropolitan Gastroenterology Group, PC - Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • UMass Memorial Medical Center
    Worcester, Massachusetts 01655, United States
  • University of Massachusetts Worcester
    Worcester, Massachusetts 01655, United States
  • Center for Digestive Health
    Troy, Michigan 48098, United States
  • Surgical Centers of Michigan
    Troy, Michigan 48098, United States
  • Surgery Center of Columbia
    Columbia, Missouri 65201, United States
  • Audrain Medical Center
    Mexico, Missouri 65265, United States
  • Center for Digestive and Liver Diseases, Inc.
    Mexico, Missouri 65265, United States
  • Barnes-Jewish Hospital - Investigational Drug Services
    Saint Louis, Missouri 63108, United States
  • Barnes-Jewish Hospital
    Saint Louis, Missouri 63110, United States
  • Center for Advanced Medicine
    Saint Louis, Missouri 63110, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • New York Hospital Queens
    Flushing, New York 11355, United States
  • Long Island Clinical Research Associates, LLP
    Great Neck, New York 11021, United States
  • Nassau Gastroenterology Associates Office Based Surgery
    Great Neck, New York 11021, United States
  • Nassau Gastroenterology Associates, P.C.
    Great Neck, New York 11021, United States
  • North Shore Primary Care, P.C.
    Great Neck, New York 11021, United States
  • Lenox Hill Endoscopy Center
    New York, New York 10075, United States
  • Synergy First
    New York, New York 11230, United States
  • Premier Medical Group of the Hudson Valley, PC
    Poughkeepsie, New York 12601, United States
  • CTRC Hospital, UNC Memorial Hospital
    Chapel Hill, North Carolina 27514, United States
  • North Carolina Memorial Hospital Endoscopy Center
    Chapel Hill, North Carolina 27514, United States
  • UNC Hospitals
    Chapel Hill, North Carolina 27514, United States
  • UNC Hospitals Endoscopy
    Chapel Hill, North Carolina 27517, United States
  • Hillsborough Campus
    Hillsborough, North Carolina 27278, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • University of Washington
    Seattle, Washington 98195, United States
  • Allegiance Research Specialists
    Wauwatosa, Wisconsin 53226, United States
  • AKH Wien Universitaetsklinik fuer Innere Medizin III
    Wien, 1090, Austria
  • AKH Wien
    Wien, 1090, Austria
  • Hospital Erasme
    Brussels, B-1070, Belgium
  • UZ Gasthuisberg - Pharmacy
    Leuven, B-3000, Belgium
  • UZ Gasthuisberg
    Leuven, B-3000, Belgium
  • Centre Hospitalier Universitaire De Liege-Domaine Universitaire du Sart Tilman
    Liege, 4000, Belgium
  • Centre Hospitalier de Mouscron
    Mouscron, 7700, Belgium
  • Oshawa Clinic
    Oshawa, Ontario L1H 1B9, Canada
  • Toronto Digestive Disease Associates Inc.
    Vaughan, Ontario L4L 4Y7, Canada
  • Hopital Beaujon
    Clichy, 92110, France
  • Hopital Huriez, CHRU de Lille
    Lille Cedex, 59037, France
  • CHRU de Lille, Pharamcie Centrale
    Lille, 59037, France
  • CIC - Hopital Cardiologique
    Lille, 59037, France
  • Hopital de l'Archet 2 - CHU de Nice
    NICE Cedex 3, 06202, France
  • Hopital Saint-Louis
    Paris, 75010, France
  • Hopital Nord
    St Priest En Jarez, 42270, France
  • Hopital Rangueil
    Toulouse Cedex 9, 31059, France
  • Robert Bosch Krankenhaus GmbH
    Stuttgart, Baden-wuerttemberg 70376, Germany
  • Universitaetsklinikum Ulm
    Ulm, Baden-wuerttemberg 89081, Germany
  • "Charite - Campus Berlin Mitte Medizinische Klinik
    Berlin, 10117, Germany
  • Charite, Universitaetsmedizin Berlin, Campus Virchow-Klinikum
    Berlin, 13353, Germany
  • Krankenhaus Martha-Maria Halle-Doelau gGmbH
    Halle, 06120, Germany
  • Universitaetsklinikum Schleswig-Holstein, Campus Kiel
    Kiel, 24105, Germany
  • Universitaetsfrauenklinikum Schleswig-Holstein
    Luebeck, 23538, Germany
  • Gastroenterologische Gemeinschaftspraxis Minden
    Minden, 32423, Germany
  • Universitaetsklinik Regensburg
    Regensburg, 93042, Germany
  • National Hospital Organization Takasaki General Medical Center
    Takasaki, Gunma 370-0829, Japan
  • Yokohama City University Medical Center
    Yokohama-Shi, Kanagawa 232-0024, Japan
  • The Jikei University Hospital
    Minato-Ku, Tokyo 105-8471, Japan
  • Keio University Hospital
    Shinjuku-Ku, Tokyo 160-8582, Japan
  • National Hospital Organization Hirosaki National Hospital
    Aomori, Toyko 036-8545, Japan
  • Chiba University Hospital
    Chiba, 260-8677, Japan
  • Pusan National University Hospital
    Busan, 602-739, Korea, Republic of
  • Yeungnam University Hospital
    Daegu, 705-717, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Kangbuk Samsung Hospital
    Seoul, 110-746, Korea, Republic of
  • Samsung Medical Center
    Seoul, 135-710, Korea, Republic of
  • Asan Medical Center
    Seoul, 138-736, Korea, Republic of
  • Academic Medical Center
    Amsterdam, 1105 AZ, Netherlands
  • University Medical Center Groningen
    Groningen, 9713GZ, Netherlands
  • Maastricht University Medical Center
    Maastricht, 6229 HX, Netherlands
  • Sykehusapoteket Asker og Baerum
    Gjettum, 1346, Norway
  • Oslo Universitetssykehus
    Oslo, 0424, Norway
  • Lovisenberg Diakonale Sykehus
    Oslo, 0440, Norway
  • Vestre Viken HF
    Rud, 1309, Norway
  • Centrum Endoskopii Zabiegowej
    Bydgoszcz, 85-168, Poland
  • NZOZ Centrum Medyczne Szpital Sw. Rodziny
    Lodz, 90-302, Poland
  • Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji w Warszawie
    Warszawa, 02-507, Poland
  • Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych W Warszawie
    Warszawa, 02-507, Poland
  • Lexmedica
    Wroclaw, 53-114, Poland
  • Military Medical Academy
    Belgrade, 11000, Serbia
  • Clinical Hospital Centre Bezanijska Kosa
    Belgrade, 11080, Serbia
  • Clinical Hospital Center Zemun, Clinical Department for Gastroenterology and Hepatology
    Zemun, 11080, Serbia

Showing the first 100 of 112 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • D'Haens GR, Reinisch W, Lee SD, Tarabar D, Louis E, Klopocka M, Klaus J, Schreiber S, Il Park D, Hebuterne X, Nagy P, Cataldi F, Martin SW, Nayak S, Banerjee A, Gorelick KJ, Sandborn WJ. Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study. Inflamm Bowel Dis. 2022 Jul 1;28(7):1034-1044. doi: 10.1093/ibd/izab215. PubMed 34427633 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2011 to primary completion in Jul 2016, 60 months.

Results were first posted in Aug 2017, 1 year 1 month after primary completion.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 60 months is above that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2011
First posted
Feb 17, 2011
StartActual
Jul 1, 2011
Primary completionActual
Jul 27, 2016
CompletionActual
Jul 27, 2016
Results first posted
Aug 31, 2017
Last update
Jun 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01298492
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Feb 17, 2011
Start date
Jul 1, 2011
Primary completion
Jul 27, 2016
Completion
Jul 27, 2016
Results posted
Aug 31, 2017
Last update
Jun 3, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ontamalimab

Start the discussion